Meeting
2023 ASCO Annual Meeting
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
Authors
Sminu (Sam) Bose
Columbia University Irving Medical Center, New York, NY
Sminu (Sam) Bose , Liner Ge , Shing M Lee , Brian Andrew Van Tine , Mark Agulnik , Mia C. Weiss , Kristine Peregrino Lacuna , Naomi Sender , Sarah Sta Ana , Frank J. Hsu , Gary K. Schwartz , Matthew Ingham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03719430
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11565)
DOI
10.1200/JCO.2023.41.16_suppl.11565
Abstract #
11565
Poster Bd #
499
Abstract Disclosures
Similar Posters
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II trial with safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin chemotherapy for the treatment of advanced soft tissue sarcoma.
First Author: Matthew Ingham
Poster
2023 ASCO Annual Meeting
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).
First Author: Xi Guo
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon
Poster
2017 ASCO Annual Meeting
Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective.
First Author: Sivan Shamai